Last reviewed · How we verify
NCT05340218
Short-term Automated Longitudinal Analysis of Speech and Language in Cognitive Impairment
NA trial testing Speech analysis in Mild Cognitive Impairment in 196 participants. Completed in 22 March 2022.
22 March 2022
Quick facts
| Lead sponsor | Accexible |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 196 |
| Start date | 1 January 2019 |
| Primary completion | 22 March 2022 |
| Estimated completion | 22 March 2022 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Speech analysis
Conditions studied
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
- Dementia — all drugs for Dementia →
Sponsor
Accexible — full company profile →
Who can join
Adults 55 to 90, any sex, with Mild Cognitive Impairment or Dementia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Validate speech analysis AI models: * To contrast the accuracy of acceXible's platform as a screening tool in the detection of people with cognitive impairment and mild dementia. * To evaluate the correlation between automatically analyzed linguistic variables and a combination of standard measures of cognition. * To assess short-term variability in language ability among older adults, and to assess which aspects of language vary during the study period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05340218
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Speech analysis
Trials testing the same drug.
- NCT05380297 — Validation of acceXible's Automated Speech Analysis Method for the Early Detection and Monitoring of Patients With Mild · NA · completed
Other recruiting trials for Mild Cognitive Impairment
Currently open trials in the same condition.
- NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
- NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
- NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting
Other Accexible trials
Trials by the same sponsor.
- NCT06044818 — Validation of Accexible as a Tool for Screening and Monitoring Depression. · completed
- NCT05534958 — UK Validation of the Automated "AcceXible" Speech Analysis Software · completed
- NCT05380297 — Validation of acceXible's Automated Speech Analysis Method for the Early Detection and Monitoring of Patients With Mild · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05340218 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Accexible
- Last refreshed: 25 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05340218.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing